Work

A phase II trial assessing pazopanib (paz) as third-line therapy for metastatic renal cell carcinoma (mRCC): Clinical outcome and temporal analysis of molecular profile.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.4571

Authors: Sumanta Kumar Pal, Dewan Md Sakib Hossain, Qifang Zhang, Chan Gao, Paul Henry Frankel, Christopher Ruel, Jeremy Jones, Courtney Carmichael, Przemyslaw Twardowski, Robert A. Figlin, Marcin Kortylewski

Institutions: City Of Hope National Medical Center, City of Hope, Beckman Research Institute, Cedars-Sinai Medical Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2599866930

Cites:

Cited by: 1

Related to: 10